Reduction of Human Anti-tetanus Toxoid Antibody in Hu-PBL-SCID Mice by Immunodominant Peptides of Tetanus Toxoid

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2004 Jul 24

PMID 15270840

Citations 4

Authors

D J Jackson

C J Elson

B M Kumpel

Affiliations

Soon will be listed here.

Abstract

Immunotherapy of murine autoimmune and allergic diseases by administration of peptides corresponding to the dominant T cell epitope is a reality. However, problems remain in applying this therapy to reduce antibody responses in humans. To overcome these difficulties, a preclinical system was developed to test the effect of immunodominant peptides from a common antigen, tetanus toxoid (TT), on the long-term human anti-TT response. Individuals whose T cells proliferated against dominant TT peptides were identified. Peripheral blood leucocytes (PBL) from these donors were injected intraperitoneally (i.p.) into mice with severe combined immunodeficiency (SCID) that had been depleted of murine natural killer (NK) cells (hu-PBL-SCID mice). Peptides or PBS were injected i.p. before a further injection of PBL and immunization with TT. The concentration of human IgG and anti-TT in murine plasma was followed for 10 weeks. The total IgG was similar in both groups. By contrast, there was a statistically significant reduction in IgG anti-TT from eight weeks onwards. It is considered that the hu-PBL-SCID model system may provide a means by which the efficacy of peptide immunotherapy for reduction of pathological antibodies in humans can be examined.

Citing Articles

Promyelocytic leukemia zinc-finger induction signs mesenchymal stem cell commitment: identification of a key marker for stemness maintenance?.

Djouad F, Tejedor G, Toupet K, Maumus M, Bony C, Blangy A Stem Cell Res Ther. 2014; 5(1):27.

PMID: 24564963 PMC: 4055047. DOI: 10.1186/scrt416.

Human platelet antigen (HPA)-1a peptides do not reliably suppress anti-HPA-1a responses using a humanized severe combined immunodeficiency (SCID) mouse model.

Jackson D, Eastlake J, Kumpel B Clin Exp Immunol. 2013; 176(1):23-36.

PMID: 24261689 PMC: 3958151. DOI: 10.1111/cei.12242.

Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: a case report.

Angelini G, Bonamonte D, Lucchese A, Favia G, Serpico R, Mittelman A J Transl Med. 2006; 4:43.

PMID: 17062151 PMC: 1630706. DOI: 10.1186/1479-5876-4-43.

Reactivity of T cells from women with antibodies to the human platelet antigen (HPA)-1a to peptides encompassing the HPA-1 polymorphism.

Jackson D, Murphy M, Soothill P, Lucas G, Elson C, Kumpel B Clin Exp Immunol. 2005; 142(1):92-102.

PMID: 16178861 PMC: 1809477. DOI: 10.1111/j.1365-2249.2005.02903.x.

References

Reece J, Geysen H, Rodda S . Mapping the major human T helper epitopes of tetanus toxin. The emerging picture. J Immunol. 1993; 151(11):6175-84. View

Dhodapkar M, Steinman R, Krasovsky J, Munz C, Bhardwaj N . Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001; 193(2):233-8. PMC: 2193335. DOI: 10.1084/jem.193.2.233. View

Berney T, Molano R, Pileggi A, Cattan P, Li H, Ricordi C . Patterns of engraftment in different strains of immunodeficient mice reconstituted with human peripheral blood lymphocytes. Transplantation. 2001; 72(1):133-40. DOI: 10.1097/00007890-200107150-00026. View

Schiffer C . Diagnosis and management of refractoriness to platelet transfusion. Blood Rev. 2002; 15(4):175-80. DOI: 10.1054/blre.2001.0164. View

Bussel J . Novel approaches to refractory immune thrombocytopenic purpura. Blood Rev. 2002; 16(1):31-6. DOI: 10.1054/blre.2001.0178. View

Rosse W . Clinical management of adult ITP prior to splenectomy: a perspective. Blood Rev. 2002; 16(1):47-9. DOI: 10.1054/blre.2001.0182. View

Kaplan C . Alloimmune thrombocytopenia of the fetus and the newborn. Blood Rev. 2002; 16(1):69-72. DOI: 10.1054/blre.2001.0187. View

Mazza G, Ponsford M, Lowrey P, Campbell M, Zajicek J, Wraith D . Diversity and dynamics of the T-cell response to MBP in DR2+ve individuals. Clin Exp Immunol. 2002; 128(3):538-47. PMC: 1906251. DOI: 10.1046/j.1365-2249.2002.01831.x. View

Massey E, Sundstedt A, Day M, Corfield G, Anderton S, Wraith D . Intranasal peptide-induced peripheral tolerance: the role of IL-10 in regulatory T cell function within the context of experimental autoimmune encephalomyelitis. Vet Immunol Immunopathol. 2002; 87(3-4):357-72. DOI: 10.1016/s0165-2427(02)00068-5. View

10.

van Kampen C, Roelen D, Versteeg-van der Voort Maarschalk M, Hoitsma A, Allebes W, Claas F . Activated HLA class I-reactive cytotoxic T lymphocytes associated with a positive historical crossmatch predict early graft failure. Transplantation. 2002; 74(8):1114-9. DOI: 10.1097/00007890-200210270-00010. View

11.

Lee P, Terasaki P, Takemoto S, Lee P, Hung C, Chen Y . All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation. 2002; 74(8):1192-4. DOI: 10.1097/00007890-200210270-00025. View

12.

Sundstedt A, ONeill E, Nicolson K, Wraith D . Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J Immunol. 2003; 170(3):1240-8. DOI: 10.4049/jimmunol.170.3.1240. View

13.

Joosten S, van Kooten C, Paul L . Pathogenesis of chronic allograft rejection. Transpl Int. 2003; 16(3):137-45. DOI: 10.1007/s00147-003-0554-x. View

14.

Shen C, Youssef A, Devine A, Bowie L, Hall A, Wraith D . Peptides containing a dominant T-cell epitope from red cell band 3 have in vivo immunomodulatory properties in NZB mice with autoimmune hemolytic anemia. Blood. 2003; 102(10):3800-6. DOI: 10.1182/blood-2002-07-2125. View

15.

Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, Okumura K . In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol. 1981; 127(1):34-8. View

16.

Morales W, Stroup M . Intracranial hemorrhage in utero due to isoimmune neonatal thrombocytopenia. Obstet Gynecol. 1985; 65(3 Suppl):20S-21S. View

17.

Mosier D, Gulizia R, Baird S, Wilson D . Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature. 1988; 335(6187):256-9. DOI: 10.1038/335256a0. View

18.

Demotz S, Lanzavecchia A, Eisel U, Niemann H, Widmann C, Corradin G . Delineation of several DR-restricted tetanus toxin T cell epitopes. J Immunol. 1989; 142(2):394-402. View

19.

Demotz S, Matricardi P, Irle C, Panina P, Lanzavecchia A, Corradin G . Processing of tetanus toxin by human antigen-presenting cells. Evidence for donor and epitope-specific processing pathways. J Immunol. 1989; 143(12):3881-6. View

20.

Kumpel B, Goodrick M, Pamphilon D, Fraser I, Poole G, Morse C . Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D- volunteers. Blood. 1995; 86(5):1701-9. View